-transparent.png){kind=logo}
Natural products are considered as promising tools for the prevention and treatment of cancer. The enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase unit of polycomb repressor complexes such as PRC2 complex that has oncogenic roles through interference with growth and metastatic potential. Several agents targeting EZH2 has been discovered but they often induce side effects in clinical trials. Recently, EZH2 has emerged as a potential target of natural products with documented anti-cancer effects and this discloses a new scenario for the development of EZH2 inhibitory strategies with agents with low cytotoxic detrimental effects. In fact, several natural products such as curcumin, triptolide, ursolic acid, sulforaphane, davidiin, tanshindiols, gambogic acid, berberine and Alcea rosea have been shown to serve as EZH2 modulators. Mechanisms like inhibition of histone H3K4, H3K27 and H3K36 trimethylation, down-regulation of matrix metalloproteinase expression, competitive binding to the S-adenosylmethionine binding site of EZH2 and modulation of tumor-suppressive microRNAs have been demonstrated to mediate the EZH2-inhibitory activity of the mentioned natural products. This review summarizes the pathways that are regulated by various natural products resulting in the suppression of EZH2, and provides a plausible molecular mechanism for the putative anti-cancer effects of these compounds.
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
December 2001,
Journal of agricultural and food chemistry,
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
August 2006,
Expert opinion on drug discovery,
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
August 1995,
The American journal of pathology,
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
March 2000,
Current opinion in drug discovery & development,
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
April 2018,
Comparative medicine,
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
January 1972,
Progress in medicinal chemistry,
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
January 1994,
Journal of natural products,
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
June 2022,
International journal of molecular sciences,
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
January 2012,
Anti-inflammatory & anti-allergy agents in medicinal chemistry,
Fahimeh Shahabipour, and
Michele Caraglia, and
Muhammed Majeed, and
Giuseppe Derosa, and
Pamela Maffioli, and
Amirhossein Sahebkar
August 1970,
Vox sanguinis,
